Rosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Patients undergoing regular hemodialysis exhibit elevated cardiovascular mortality.
• Uremic dyslipidemia and inflammation contribute to atherosclerosis in this population.
• The efficacy of rosuvastatin in dialysis patients remained uninvestigated.

Purpose of the Study:

• To assess the impact of rosuvastatin therapy on lipid profiles, lipoproteins, and inflammation markers in hemodialysis patients.
• To evaluate rosuvastatin's effectiveness in managing dyslipidemia and inflammation in end-stage renal disease.

Main Methods:

• A 3-month, double-blind, randomized, placebo-controlled trial involving 59 hemodialysis patients.
• Participants were assigned to receive either rosuvastatin 10 mg/day (n=28) or a placebo (n=31).
• Measurements of lipids, lipoproteins, and high-sensitivity C-reactive protein (hs-CRP) were conducted at baseline, 30 days, and 3 months.

Main Results:

• The rosuvastatin group showed significant reductions in total cholesterol, LDL cholesterol, and non-HDL cholesterol compared to baseline (p<0.05).
• No significant lipid changes were observed in the placebo group.
• High-sensitivity CRP levels were significantly lower in the rosuvastatin group versus placebo at 3 months (p<0.01).

Conclusions:

• Rosuvastatin calcium, at a dosage of 10 mg/day, demonstrated efficacy in improving lipid profiles for hemodialysis patients.
• The therapy also effectively reduced high-sensitivity C-reactive protein levels, indicating an anti-inflammatory effect.
• These findings suggest rosuvastatin is a viable option for managing cardiovascular risk factors in this patient cohort.